ABO-201 C9ORF clinical clearance
Arbor lists ABO-201 for C9ORF-related ALS and FTD using AAV-delivered nuclease excision. Its financing announcement funds progression of CNS programs toward IND/CTA filings.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- This is a program-specific authorization candidate, not an announced near-term FDA decision; pin ALS versus FTD rules.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
IND-enabling program — no filing or clearance date confirmed
Company context
Company-authored LinkedIn About explicitly states Type: Privately Held and links arbor.bio. Opened and checked October 31, 2026. This is an undated company self-report, not independent registry proof. The opened 2026 Metagenomi annual report also calls Arbor private.
Potential outcome market
Will Arbor publicly confirm clearance to begin human dosing of ABO-201 for C9ORF-related disease by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.